Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals•Philadelphia, PA

3d•$212,000 - $318,000•Remote

About The Position

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for global and US payer evidence strategy across marketed assets in Jazz Pharmaceuticals’ neurology portfolio. The role maximizes brand potential, defends product value, supports expanded access, and drives evidence generation across the post-launch lifecycle, including label expansions, new formulations, line extensions, and competitive market shifts. The Director translates commercial, access, and policy priorities into methodologically sound evidence plans and deliverables, including global economic models, real-world observational studies, patient registries, Global Value Dossiers, and US AMCP dossiers. The position contributes to Integrated Evidence Generation Plan governance and brand strategy forums, and leads both global and US work: serving as the designated US HEOR lead while collaborating with EU/International HEOR colleagues on HTA reassessments and post-launch evidence packages. The role leads lifecycle evidence strategies and payer-relevant research, supports inline value defense and reimbursement reviews, provides US payer field enablement, develops health economic models, and partners across Market Access, Medical Affairs, Commercial, Regulatory, Biostatistics, and RWE. It also oversees external vendors and budgets, drives publications and conference presentations, and provides informal mentorship and technical guidance to colleagues.

Requirements

Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
A minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm.
Demonstrated experience leading HEOR strategy and executing evidence deliverables for marketed pharmaceutical products, including lifecycle management, label expansions, and value defense.
Experience serving as US HEOR launch lead for at least two assets, or as a country-level HTA lead.
Comprehensive working knowledge of the US managed care landscape, including commercial payers, Medicare Part D and Advantage, Medicaid, PBMs, and integrated delivery networks, as well as global HTA environments.
Technical expertise building, adapting, and validating economic models, including Markov, partitioned survival, microsimulation, and dynamic budget impact models, using mature real-world and clinical trial data.
Track record collaborating with US Market Access, Pricing and Contracting, and Payer Field Teams to develop customer-facing tools, interactive budget models, and AMCP dossiers in accordance with applicable requirements.
Understanding of post-launch evidence challenges in rare diseases, including registry management, natural history benchmarks, long-term surrogate endpoint validation, and specialized HTA reimbursement mechanisms.
Working knowledge of major US and global healthcare databases, such as IQVIA, Optum, MarketScan, Medicare SAF, disease-specific registries, and electronic health records, and advanced epidemiological methods for comparative research.
Ability to work collaboratively with regional HEOR teams, particularly EU/International, on HTA reassessment packages and local market execution.
Ability to balance evidence strategy with hands-on execution of technical deliverables, including dossiers, models, observational research protocols, and publications.
Exceptional verbal, written, and presentation skills, and ability to influence cross-functional teams without direct authority and defend methodologies before payers, HTA authorities, and scientific reviewers.
Deep understanding of US payers and population health decision-makers, including oncology pathways.
Strong peer-reviewed publication record in health economics and outcomes research.

Nice To Haves

Experience with oncology assets.
Preferred above-country HEOR product leadership experience.
Experience conducting post-marketing real-world evidence research, patient registry studies, and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions.
Substantial experience collaborating with regional HEOR teams to deliver evidence packages for global HTA reassessments, renewals, or pricing renegotiations.
Experience as the US HEOR lead or delivering US pre-launch HEOR work, such as AMCP PIE dossiers, US budget impact models, and payer field enablement, or significant exposure to these deliverables from a global role.

Responsibilities

Lead HEOR evidence strategies supporting supplemental regulatory filings, new indications, line extensions, expanded patient populations, and novel delivery formulations or devices.
Partner with Medical Affairs, Clinical Development, and Biostatistics to incorporate payer-relevant comparative endpoints, patient-reported outcomes, and health-related quality-of-life measures into Phase 3b/4 protocols, pragmatic trials, and expanded access programs.
Work with Market Access to evaluate evidence requirements across multi-indication lifecycles and deliver comparative effectiveness and economic evidence for access following label expansions.
Collaborate on long-term prospective registries, natural history extensions, and post-authorization safety and efficacy studies for rare disease products.
Identify competitive threats, changes in standard of care, and generic or biosimilar erosion; design and execute comparative effectiveness, adherence, and burden-of-illness studies to defend product differentiation and access positioning.
Partner with EU/International HEOR teams on evidence strategies and analytical packages for HTA reassessments, conditional reimbursement reviews, and price renegotiations.
Design real-world data collection programs to fulfill post-launch evidence commitments and support conversion of conditional or temporary reimbursement to permanent market access.
Direct maintenance and substantive updates of Global Value Dossiers, systematic literature reviews, and meta-analyses.
Serve as the designated US HEOR expert for assigned inline products and translate US brand and access priorities into health economic deliverables.
Lead authoring, annual maintenance, and reactive dissemination of AMCP dossiers, unbranded value summaries, and state Medicaid submission dossiers.
Partner with the US Payer Field Team and US Medical Affairs to develop and train teams on customer-facing economic models and reactive scientific presentations.
Ensure US HEOR deliverables, models, and field materials comply with requirements governing communication of Health Care Economic Information, including FDAMA Section 114, the 21st Century Cures Act, and FDA guidance.
Collaborate with US Market Access, Pricing, and Contracting to assess outcomes-based agreements and establish real-world endpoint tracking frameworks using claims or EHR data.
Monitor US health policy and develop evidence plans and materials related to policy changes and evaluations by ICER and other value assessment bodies.
Formulate and execute health economic modeling strategies for marketed products, including cost-effectiveness, cost-utility, budget impact, and cost-offset models.
Adapt economic models to incorporate mature clinical and real-world data, including long-term survival, real-world treatment patterns, dosing adherence, and observational utility weights.
Apply modeling approaches to address uncertainty in mature disease states, treatment sequencing, treatment switching, and heterogeneous rare disease trajectories.
Build transparent, user-friendly US commercial, Medicare Advantage, and state Medicaid budget impact models with customizable formulary tiering, rebate, and market penetration scenarios.
Represent GVHEOR in Integrated Evidence Generation Plan governance for inline assets and align post-marketing studies and budget milestones with brand objectives.
Partner with Market Access to ensure payer evidence plans validate and update product value stories based on real-world utilization and payer coverage changes.
Coordinate with Medical Affairs, Commercial Brand Leads, Regulatory Affairs, Biostatistics, and RWE on post-launch evidence initiatives.
Drive post-marketing HEOR publications, lead manuscript writing and submission, and present findings at relevant congresses.
Manage project budgets and oversee external HEOR consultancies, academic partners, and contract research organizations.
Provide informal mentorship and technical guidance to associate directors, managers, and fellows across the Evidence and Value Generation department.